| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6368632 | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2013
(10 years ago) | |
| US7547452 | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2013
(10 years ago) | |
| US6110921 | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2013
(10 years ago) | |
| US5965168 | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2013
(10 years ago) | |
|
US6110921 (Pediatric) | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2014
(9 years ago) | |
|
US5965168 (Pediatric) | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2014
(9 years ago) | |
|
US7547452 (Pediatric) | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2014
(9 years ago) | |
|
US6368632 (Pediatric) | JANSSEN PHARMS | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2014
(9 years ago) | |
| US5688801 | JANSSEN PHARMS | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
Nov, 2014
(9 years ago) | |
|
US5688801 (Pediatric) | JANSSEN PHARMS | Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
May, 2015
(8 years ago) | |
| US5792477 | JANSSEN PHARMS | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
May, 2017
(7 years ago) | |
| US5916598 | JANSSEN PHARMS | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May, 2017
(7 years ago) | |
| US6403114 | JANSSEN PHARMS | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
May, 2017
(7 years ago) | |
|
US5792477 (Pediatric) | JANSSEN PHARMS | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
Nov, 2017
(6 years ago) | |
|
US5916598 (Pediatric) | JANSSEN PHARMS | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
Nov, 2017
(6 years ago) | |
|
US6403114 (Pediatric) | JANSSEN PHARMS | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
Nov, 2017
(6 years ago) | |
| US6596316 | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Dec, 2018
(5 years ago) | |
| US6379703 | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Dec, 2018
(5 years ago) | |
| US6194006 | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Dec, 2018
(5 years ago) | |
|
US6596316 (Pediatric) | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Jun, 2019
(4 years ago) | |
|
US6194006 (Pediatric) | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Jun, 2019
(4 years ago) | |
|
US6379703 (Pediatric) | JANSSEN PHARMS | Preparation of microparticles having a selected release profile |
Jun, 2019
(4 years ago) | |
| US6667061 | JANSSEN PHARMS | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
|
US6667061 (Pediatric) | JANSSEN PHARMS | Preparation of injectable suspensions having improved injectability |
Nov, 2020
(3 years ago) | |
Risperdal Consta is owned by Janssen Pharms.
Risperdal Consta contains Risperidone.
Risperdal Consta has a total of 24 drug patents out of which 24 drug patents have expired.
Expired drug patents of Risperdal Consta are:
- US6368632
- US7547452
- US6110921
- US5965168
- US6110921*PED
- US5965168*PED
- US7547452*PED
- US6368632*PED
- US5688801
- US5688801*PED
- US5792477
- US5916598
- US6403114
- US5792477*PED
- US5916598*PED
- US6403114*PED
- US6596316
- US6379703
- US6194006
- US6596316*PED
- US6194006*PED
- US6379703*PED
- US6667061
- US6667061*PED
Risperdal Consta was authorised for market use on 12 April, 2007.
Risperdal Consta is available in injectable;intramuscular dosage forms.
Risperdal Consta can be used as treatment of schizophrenia.
The generics of Risperdal Consta are possible to be released after 25 November, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-597) | May 15, 2012 |
| New Indication(I-596) | May 15, 2012 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 12 April, 2007
Treatment: Treatment of schizophrenia
Dosage: INJECTABLE;INTRAMUSCULAR
RISPERDAL CONSTA family patents
